Current Neoadjuvant Treatment Options for HER2 Positive Breast Cancer

Biologics: Targets and Therapy - New Zealand
doi 10.2147/btt.s22917
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Targeted Therapeutic Options and Future Perspectives for HER2-positive Breast Cancer

Signal Transduction and Targeted Therapy
Cancer ResearchGenetics
2019English

Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?

Therapeutic Advances in Medical Oncology
Oncology
2018English

Current Approaches and Future Directions in the Treatment of HER2-positive Breast Cancer

Cancer Treatment Reviews
MedicineOncologyRadiologyNuclear MedicineImaging
2013English

Optimal Treatment of Early Stage HER2-positive Breast Cancer

Cancer
Cancer ResearchOncology
2018English

Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer

New England Journal of Medicine
Medicine
2012English

Targeted Therapy for HER2 Positive Breast Cancer

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2013English

New Developments in the Treatment of HER2-positive Breast Cancer

Breast Cancer: Targets and Therapy
Oncology
2012English

Current Treatment of Early Breast Cancer: Adjuvant and Neoadjuvant Therapy

F1000Research
GeneticsMolecular BiologyPharmacologyBiochemistryMicrobiology ImmunologyMedicineToxicologyPharmaceutics
2014English

Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer

Frontiers in Oncology
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy